Nature Cell Keeps Hopes Up For JointStem Despite Conditional Approval Rejection

Nature Cell remains positive on its degenerative osteoarthritis therapy JointStem as it seeks to move on to a Phase III study in South Korea, and reattempts to seek conditional approval after its initial such filing based on Phase II results was rejected earlier this year.